Renew Bio's Blood Test Offers Cellular 'GPS' for Neurodegeneration

PLEASANT GROVE, UT – August 07, 2026 – For decades, diagnosing neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS has been a process of elimination, relying on a combination of clinical symptoms, costly brain scans, and invasive spinal taps. Existing blood tests, while promising, often act like smoke detectors, confirming a fire but offering few clues about its precise location or intensity. Today, that landscape may be fundamentally changing.

Renew Biotechnologies, a Utah-based company, has published peer-reviewed research in Frontiers in Neurology detailing a breakthrough technique that acts less like a smoke detector and more like a cellular GPS for the brain. By analyzing fragments of DNA circulating in the blood, their NeuroLens® platform can identify the specific types of neurons that are dying, providing an unprecedented window into the biological origins of these devastating diseases.

This move from detecting generalized injury to pinpointing cell-of-origin marks a significant leap in diagnostics. It promises not just earlier and more accurate detection, but a more nuanced understanding of disease progression that could transform how we develop and deploy treatments.

The Science of Cellular Insight

When neurons in the brain die, they release fragments of their DNA into the bloodstream. These fragments, known as cell-free DNA (cfDNA), carry a unique chemical signature called methylation—epigenetic markers that act like a cellular return address, indicating which type of cell they came from. Renew's technology harnesses this insight.

Unlike current blood biomarkers that primarily measure disease-related proteins (like amyloid and tau in Alzheimer's) or general nerve damage (like neurofilament light chain), Renew's approach decodes the methylation patterns on the DNA itself. To do this, the company developed a comprehensive 'human brain methylation reference atlas,' mapping the unique signatures of various neuronal and glial cell types. When cfDNA is detected in a blood sample, its methylation pattern can be cross-referenced with this atlas to determine its origin.

"Blood-based biomarkers have transformed the field of neurodegenerative disease, but many currently available tests provide limited information about where neurodegeneration is occurring within the brain," said Chad Pollard, CEO and Co-Founder of Renew Biotechnologies. "Our goal is to develop biomarkers that not only detect neurodegeneration, but also provide greater biological context by identifying the neuronal populations likely contributing to those signals and how quickly those populations are dying."

The proof-of-concept study, which analyzed 137 blood samples from individuals with Alzheimer's, Parkinson's, ALS, mild cognitive impairment, and healthy controls, yielded impressive results. The platform successfully identified cfDNA signatures corresponding to the specific neurons known to be vulnerable in each disease: cortical neurons in Alzheimer's, dopaminergic neurons in Parkinson's, and spinal motor neurons in ALS. Models using these signatures could distinguish between diseased and healthy individuals with a high degree of accuracy, achieving area under the curve (AUC) values over 0.85.

Crucially, the technology uses nanopore sequencing to analyze native DNA, bypassing chemical treatments like bisulfite conversion that can damage the already scarce cfDNA and introduce biases. "Native cfDNA methylation sequencing opens the door to a fundamentally different way of studying neurodegeneration," explained Tim Jenkins, Renew's Vice President of Research & Discovery. "By combining brain cell-type-specific methylation biology with native sequencing, we believe this approach can complement existing blood biomarkers by providing greater insight into the biological processes underlying neurodegeneration."

Reshaping the Diagnostic Landscape

The market for neurodegenerative diagnostics, valued at over $5 billion, is rapidly pivoting toward less invasive blood-based solutions. The limitations of current methods are a major driver. PET scans are expensive and not widely accessible. Spinal taps are invasive and can be daunting for patients. And while existing blood tests for proteins like p-tau217 have been a major step forward for Alzheimer's, they still don't tell the whole story.

"We can see the smoke with current tests, but we can't tell which part of the forest is on fire. A technology that points to the specific trees burning would be a game-changer for both diagnosis and for monitoring how well a new drug is working," an independent neurologist not involved with the study commented. This is particularly critical in diseases like ALS, where the diagnostic delay can be nearly a year, a devastating loss of time for patients facing a rapid decline.

Renew's NeuroLens® platform enters this landscape with a unique value proposition: neuroanatomic resolution from a simple blood draw. It offers the potential to not only differentiate between diseases that can present with similar early symptoms but also to monitor the rate of specific cell death in real-time. This could be invaluable for clinical trials, allowing researchers to quickly see if a therapeutic is successfully protecting a targeted neuronal population.

From Lab Bench to Patient Bedside

While the science is compelling, the path to widespread clinical use requires navigating a complex regulatory and commercial landscape. NeuroLens® is currently available as a Research Use Only (RUO) product, primarily for academic and pharmaceutical partners. The company's next step is to offer it as a Laboratory Developed Test (LDT), which would allow clinicians to order the test for patients from Renew's CLIA-certified and CAP-accredited laboratory.

This transition requires extensive analytical and clinical validation to prove the test is not only accurate but provides clinically meaningful information. Since completing the initial study, Renew has already processed over 2,000 additional patient samples to further validate the technology. The company, founded in 2022 and bolstered by a $23 million Series A funding round, appears well-equipped for this journey. Its consolidation of subsidiaries Wasatch BioLabs and Resonant earlier this year was a strategic move to integrate its deep expertise in sequencing-based diagnostics.

The ultimate hurdles will be cost and reimbursement. Advanced sequencing tests can be expensive, and securing coverage from insurance providers is key to ensuring broad and equitable patient access. However, the potential to replace or reduce the need for more expensive procedures like PET scans could present a compelling economic argument for payers.

For patients and their families, the implications are profound. An earlier, more definitive diagnosis can end the painful uncertainty of a diagnostic odyssey. It can open doors to clinical trials, allow for earlier planning, and provide a clearer path forward. "For families navigating these devastating diseases, any tool that provides clarity and a faster path to a diagnosis is a profound source of hope," noted a representative from a patient advocacy group. By providing a clearer, more detailed picture of what is happening inside the brain, Renew's technology promises to do just that, complementing existing tools and potentially heralding a new era of precision neurology.